M A Perera

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
    Minoli A Perera
    University of Chicago, Section of Genetic Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, Division of Biological Sciences, Department of Medicine, Chicago, IL 60637, USA
    Expert Opin Drug Metab Toxicol 6:17-28. 2010
  2. pmc Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution
    Ashraf G Madian
    Committee of Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA
    BMC Pharmacol Toxicol 15:69. 2014
  3. pmc Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
    M A Perera
    Committee on Clinical Pharmacology and Pharmacogenomics, Division of Biological Sciences, University of Chicago, Chicago, IL, USA
    Pharmacogenomics J 9:49-60. 2009
  4. pmc The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans
    M A Perera
    Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 89:408-15. 2011
  5. doi request reprint Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
    Minoli A Perera
    Sections of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Pharmacotherapy 28:755-68. 2008
  6. pmc African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity
    James P Lodolce
    Department of Medicine, University of Chicago, Chicago, IL 60612, USA
    J Immunol 184:7001-9. 2010

Collaborators

  • R A Kittles
  • M J Ratain
  • Timothy B Niewold
  • Federico Innocenti
  • Ashraf G Madian
  • James P Lodolce
  • Navin Pinto
  • Arun Panigrahi
  • Mark F Logsdon
  • Beverly S Franek
  • Sarah J Bartulis
  • Lesley Rhee
  • Nancy M McGreal
  • Stephen B Hanauer
  • Nathan A Ellis
  • Erin J Adams
  • Meenakshi Jolly
  • Lauren E Kolodziej
  • David L Boone
  • Silvia N Kariuki

Detail Information

Publications6

  1. doi request reprint The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
    Minoli A Perera
    University of Chicago, Section of Genetic Medicine and Committee on Clinical Pharmacology and Pharmacogenomics, Division of Biological Sciences, Department of Medicine, Chicago, IL 60637, USA
    Expert Opin Drug Metab Toxicol 6:17-28. 2010
    ....
  2. pmc Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution
    Ashraf G Madian
    Committee of Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA
    BMC Pharmacol Toxicol 15:69. 2014
    ..We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation...
  3. pmc Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
    M A Perera
    Committee on Clinical Pharmacology and Pharmacogenomics, Division of Biological Sciences, University of Chicago, Chicago, IL, USA
    Pharmacogenomics J 9:49-60. 2009
    ..This study marks the first systematic evaluation of coding and noncoding variation that may contribute to CYP3A phenotypic variability...
  4. pmc The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans
    M A Perera
    Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Pharmacol Ther 89:408-15. 2011
    ..Our regression model, encompassing both genetic and clinical variables, explained 40% of the variability in warfarin dose in African-American subjects, significantly more than any model thus far...
  5. doi request reprint Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
    Minoli A Perera
    Sections of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Pharmacotherapy 28:755-68. 2008
    ..In addition, ethical and logistic implications of pharmacogenetic testing exist...
  6. pmc African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity
    James P Lodolce
    Department of Medicine, University of Chicago, Chicago, IL 60612, USA
    J Immunol 184:7001-9. 2010
    ..This is the first report of an association between TNFAIP3 polymorphisms and autoimmunity in African-Americans...